Medicine database
Search 507 medicines from FDA open data alongside Baxtra’s twelve Phase 1 investigational medical countermeasures. Find records by generic or brand name, pharmacologic class, route, indication or mechanism, then open a structured reference view.
The database lists 519 medicines in this public extract. A small number of records are held back where the marketing authorisation holder has asked us not to republish their labelling; the count of held-back records is not published.
Baxtra’s own investigational records appear here for completeness — all twelve disclosed programmes, each with the full nineteen-field record and a linked fact sheet in the document library. One Baxtra programme has no record because its designation is withheld.
The page is cleared for public release under public revision 21 of 41. One section was withheld from this page under the disclosure policy. Material retained but not published in this revision is outside the scope of this publication. Requests for withheld material may be sent to disclosure@baxtra.pages.dev.
Established pharmacologic classes
Top 12 established pharmacologic classes among the FDA records. Select a bar to filter the database.
Loading…
| Medicine | Class | Form / route | Status |
|---|
Where these records come from
openFDA label API
Indications, dosing, warnings, adverse reactions, mechanism of action, contraindications, interactions and pregnancy text are extracted from the most recent structured product label published for each generic ingredient at api.fda.gov/drug/label.json.
openFDA NDC directory
Brand names, dosage form, route, active ingredient strength, labeller, product type and DEA schedule come from api.fda.gov/drug/ndc.json. Established pharmacologic class is the FDA's own classification.
Baxtra pipeline records
Our twelve Investigational Phase 1 candidates are described from programme documentation and flagged throughout. They have no approval anywhere in the world and cannot be prescribed.
BX-101 Nipavir targets Nipah virus infection, including henipavirus encephalitis and respiratory disease. The oral small-molecule fusion (F) glycoprotein inhibitor locks the prefusion F trimer’s hydrophobic pocket, preventing the six-helix bundle transition required for viral-envelope fusion, entry and syncytium formation. Nipah has a 40–75% case fatality rate, rising to approximately 90% in some Bangladesh outbreaks, and no approved therapeutic. SENTINEL-1 (NCT-BX0101-01) is enrolling 31 of 48 healthy volunteers; activity covers Bangladesh and Malaysia Nipah genotypes and Hendra virus, with an unbound brain-to-plasma ratio of 0.42.
BX-204 Marburavir is an intravenous nucleoside analogue L-polymerase inhibitor with oral step-down for Marburg virus disease. Its intracellular triphosphate causes delayed chain termination and lethal mutagenesis of the negative-sense genome, covering Marburg, Ravn, Zaire and Sudan viruses. Marburg outbreaks have reported 24–88% case fatality and have no licensed vaccine or therapeutic. CORDON-1 (NCT-BX0204-01) has enrolled 24 of 36 participants.
BX-308 Prionex is an intrathecal gapmer antisense oligonucleotide for sporadic and genetic Creutzfeldt–Jakob disease. It recruits RNase H1 to PRNP transcripts and lowers normal cellular prion protein, the obligate substrate required by every prion strain. CJD is invariably fatal, with median survival of four to six months from onset, and prions resist standard autoclaving, formalin and alcohol. VIGIL-0 (NCT-BX0308-01) has enrolled 12 of 24 participants; CSF prion protein lowering is 38% at 40 mg.
BX-412 Cehafex is an intravenous cocktail of two non-competing human IgG1 antibodies for Crimean-Congo haemorrhagic fever. One binds the conserved CCHFV Gc fusion loop to block entry; the other binds GP38 and recruits Fc-mediated clearance, so single-epitope escape remains neutralised. CCHF is a WHO priority pathogen, carried by Hyalomma ticks across approximately 30 countries, with 10–40% case fatality and documented healthcare-worker transmission. BASTION-1 (NCT-BX0412-01) has enrolled 38 of 54 participants; the 26-day half-life supports a single-visit regimen.
Text is truncated for readability. Always consult the full prescribing information. Source: U.S. Food & Drug Administration open data, open.fda.gov. Retrieved August 2026. The FDA does not endorse this presentation of its data.